Who
Konstantinos Xynos
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Replimune Group.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $902K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Dec 2022
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $148K11,447 at $12.97 | filing |
| 10 Aug 2026filed 12 Aug 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $148K11,447 at $12.97 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $71K14,023 at $5.08 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $71K14,023 at $5.08 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 Dec 2025filed 19 Dec 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $66K7,248 at $9.10 | filing |
| 20 May 2025filed 22 May 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $64K7,952 at $8.06 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Nov 2024filed 20 Nov 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $78K7,246 at $10.78 | filing |
| 7 Jun 2024filed 10 Jun 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $119K15,881 at $7.50 | filing |
| 16 May 2024filed 20 May 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $41K6,367 at $6.47 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —26,665 at $0.00 | filing |
| 16 Nov 2023filed 17 Nov 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $80K7,313 at $10.92 | filing |
| 16 May 2023filed 18 May 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $14K771 at $18.05 | filing |
News
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026REPL · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Konstantinos Xynos; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.